Paul Bastelica, Antoine Labbe, Marwan Sahyoun, Christophe Baudouin, Cédric Lamirel, Muriel Poli, Jean-Paul Renard, Antoine Rousseau, Cédric Schweitzer, Florent Aptel
{"title":"Patient Preferences and Understanding of Glaucoma Treatment: A Nationwide Survey by the French Glaucoma Society.","authors":"Paul Bastelica, Antoine Labbe, Marwan Sahyoun, Christophe Baudouin, Cédric Lamirel, Muriel Poli, Jean-Paul Renard, Antoine Rousseau, Cédric Schweitzer, Florent Aptel","doi":"10.1007/s12325-025-03353-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Glaucoma treatment predominantly involves the use of topical anti-glaucoma eye drops, with patient adherence influenced by individual preferences. This study aimed to assess these preferences and highlight the importance of personalized treatment approaches among ophthalmologists.</p><p><strong>Methods: </strong>This French multicenter, cross-sectional study involved 21 ophthalmologists-members of the Board of Directors of the French Society of Glaucoma-from both public and private practices, who distributed a standardized questionnaire to their patients with glaucoma. The questionnaire collected data on demographics, treatment-related experiences, patient preferences, and the prioritization of six treatment criteria: cost, efficacy, dosing frequency, side effects, environmental impact, and ease of use.</p><p><strong>Results: </strong>A total of 798 patients with glaucoma participated. There was no strong preference between multi-dose bottles and single-dose units (32.0% vs. 37.4%, respectively, with 29.2% of patients showing no preference). Side effects were reported by 31.8% of patients, and the use of artificial tears was significantly higher among those with longer treatment durations (31.3% for ≤ 2 years vs. 65.6% for > 20 years, p = 0.001). Notably, 63% of patients were unaware that their eye drops could contain preservatives. Regarding generics, 29.9% of patients had previously used one, while only 25.6% were willing to switch from their prescribed brand to a generic equivalent. Adherence was suboptimal, with only 66.2% of patients reporting being compliant. Younger age (p < 0.001) and lack of awareness about preservatives (p < 0.001) were significantly associated with non-adherence. When ranking treatment criteria, patients prioritized efficacy, followed by side effects, ease of use, cost, and environmental impact.</p><p><strong>Conclusion: </strong>This nationwide survey conducted by the French Glaucoma Society underscores the diversity of patient preferences and the critical need for personalized glaucoma care. A substantial proportion of patients feels insufficiently informed about preservatives and generics, which may negatively impact adherence. Enhanced patient education and individualized treatment strategies are essential for improving outcomes.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.0000,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12325-025-03353-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Glaucoma treatment predominantly involves the use of topical anti-glaucoma eye drops, with patient adherence influenced by individual preferences. This study aimed to assess these preferences and highlight the importance of personalized treatment approaches among ophthalmologists.
Methods: This French multicenter, cross-sectional study involved 21 ophthalmologists-members of the Board of Directors of the French Society of Glaucoma-from both public and private practices, who distributed a standardized questionnaire to their patients with glaucoma. The questionnaire collected data on demographics, treatment-related experiences, patient preferences, and the prioritization of six treatment criteria: cost, efficacy, dosing frequency, side effects, environmental impact, and ease of use.
Results: A total of 798 patients with glaucoma participated. There was no strong preference between multi-dose bottles and single-dose units (32.0% vs. 37.4%, respectively, with 29.2% of patients showing no preference). Side effects were reported by 31.8% of patients, and the use of artificial tears was significantly higher among those with longer treatment durations (31.3% for ≤ 2 years vs. 65.6% for > 20 years, p = 0.001). Notably, 63% of patients were unaware that their eye drops could contain preservatives. Regarding generics, 29.9% of patients had previously used one, while only 25.6% were willing to switch from their prescribed brand to a generic equivalent. Adherence was suboptimal, with only 66.2% of patients reporting being compliant. Younger age (p < 0.001) and lack of awareness about preservatives (p < 0.001) were significantly associated with non-adherence. When ranking treatment criteria, patients prioritized efficacy, followed by side effects, ease of use, cost, and environmental impact.
Conclusion: This nationwide survey conducted by the French Glaucoma Society underscores the diversity of patient preferences and the critical need for personalized glaucoma care. A substantial proportion of patients feels insufficiently informed about preservatives and generics, which may negatively impact adherence. Enhanced patient education and individualized treatment strategies are essential for improving outcomes.
期刊介绍：
Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged.
The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
